Literature DB >> 15303463

Recent advances in biological therapy for inflammatory bowel disease.

Jelica Kurtovic1, Isidor Segal.   

Abstract

Immune system is a major determinant of pathophysiology of inflammatory bowel disease (IBD), and cytokines are well known mediators of immune system. Recently, informations on pro-inflammatory cytokines and their role in IBD have led to development of potential therapeutic approach to manipulate these cytokines and there by inhibiting inflammation in IBD. These therapeutic approaches include inhibitors of the tumour necrosis factor (TNF)-alpha lymphocyte trafficking, type 1 T helper (Th1) cell polarization and nuclear factor type beta; immunoregulatory cytokines and various growth factors. Studies on these therapies have documented variable results and the outcomes of many clinical trials are awaited. However, these potential therapies, if become real may revolutionise approach in patients with IBD. Analysis of the inflammed mucosa from patients with Crohn disease (CD) and ulcerative colitis (UC) have shown increased expression of certain proinflammatory cytokines such as interleukin-1 (IL-1), interleukin 6 (IL-6) and TNF-alpha. The latter is important in the recruitment of neutrophils into inflammed tissue, a process which results from three physiological steps: (i) rolling, (ii) adhesion, and (iii) transendothelial migration. Understanding of the biology of chronic inflammation has expanded the therapies available for IBD and particularly CD. At present, the biological therapies that are being used in clinical practice or investigated for the treatment of IBD are predominantly proteins, usually delivered intravenously or subcutaneously. The therapies used include: 1. TNF-alpha inhibitors: infliximab, CDP 571, etanercept, onercept, CNI- 1493 and thalidomide. 2. Inhibitors of lymphocyte trafficking: natalizumab, LPD-02 and ICAM-1. 3. Inhibitors of Th1 polarization: monoclonal antibodies for IL-12, interferon (IFN)-gamma and anti IFN-gamma. 4. Immunoregulatory cytokines: IL-10 and IL-11. 5. Inhibitors of nuclear factor kappa (beta NF-kbeta.) 6. Growth factors: epidermal growth factor (EGF) and Keratinocyte growth factor (KGF).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15303463

Source DB:  PubMed          Journal:  Trop Gastroenterol        ISSN: 0250-636X


  19 in total

1.  Myosin light chain kinase inhibitor inhibits dextran sulfate sodium-induced colitis in mice.

Authors:  Xiaochang Liu; Jianming Xu; Qiao Mei; Liang Han; Jian Huang
Journal:  Dig Dis Sci       Date:  2012-07-10       Impact factor: 3.199

Review 2.  Managing Crohn disease in children and adolescents : focus on tumor necrosis factor antagonists.

Authors:  Shehzad A Saeed; Wallace V Crandall
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

3.  Anti-inflammatory effects of phytosteryl ferulates in colitis induced by dextran sulphate sodium in mice.

Authors:  M S Islam; T Murata; M Fujisawa; R Nagasaka; H Ushio; A M Bari; M Hori; H Ozaki
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

4.  The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model.

Authors:  Antonio Ramón Martín; Isabel Villegas; Marina Sánchez-Hidalgo; Catalina Alarcón de la Lastra
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

5.  Preventive rather than therapeutic treatment with high fiber diet attenuates clinical and inflammatory markers of acute and chronic DSS-induced colitis in mice.

Authors:  Ana Letícia Malheiros Silveira; Adaliene Versiani Matos Ferreira; Marina Chaves de Oliveira; Milene Alvarenga Rachid; Larissa Fonseca da Cunha Sousa; Flaviano Dos Santos Martins; Ana Cristina Gomes-Santos; Angelica Thomaz Vieira; Mauro Martins Teixeira
Journal:  Eur J Nutr       Date:  2015-10-12       Impact factor: 5.614

6.  Effect of salicin on gut inflammation and on selected groups of gut microbiota in dextran sodium sulfate induced mouse model of colitis.

Authors:  Nirmal Verma; Ravi Verma; Reena Kumari; Raju Ranjha; Jaishree Paul
Journal:  Inflamm Res       Date:  2013-11-17       Impact factor: 4.575

7.  Enhanced transferrin receptor expression by proinflammatory cytokines in enterocytes as a means for local delivery of drugs to inflamed gut mucosa.

Authors:  Efrat Harel; Abraham Rubinstein; Aviram Nissan; Elena Khazanov; Mirela Nadler Milbauer; Yechezkel Barenholz; Boaz Tirosh
Journal:  PLoS One       Date:  2011-09-06       Impact factor: 3.240

8.  Novel Pharmacological Approaches for Inflammatory Bowel Disease: Targeting Key Intracellular Pathways and the IL-23/IL-17 Axis.

Authors:  Leo R Fitzpatrick
Journal:  Int J Inflam       Date:  2012-03-15

9.  Colon-targeted delivery of live bacterial cell biotherapeutics including microencapsulated live bacterial cells.

Authors:  Satya Prakash; Aleksandra Malgorzata Urbanska
Journal:  Biologics       Date:  2008-09

10.  A Picrorhiza kurroa derivative, picroliv, attenuates the development of dextran-sulfate-sodium-induced colitis in mice.

Authors:  De-Kui Zhang; Jian-Jie Yu; Yu-Min Li; Li-Na Wei; Yi Yu; Yan-Hu Feng; Xiang Wang
Journal:  Mediators Inflamm       Date:  2012-10-16       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.